Please assess the completion status of the following clinical trial:

Trial Title: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent signed~2. Male and female ≥18 years old;~3. Patients hospitalized for clinically suspected CAP, defined as the occurrence of (within 48h from hospital admission):~   1. at least 1 of the following signs/symptoms: dyspnea, cough, purulent sputum, crackles (rales) and/or rhonchi~  2. body temperature \> 38°C or \<36°C (before or during admission) or leucocytosis (\> local ULN)~  3. new/increased pulmonary infiltrate(s) by chest imaging~4. Need for non-invasive supplemental oxygen (NIAID-OS 5-6; Appendix 14.4.1);~5. SpO2 \<92% at room air, or PaO2/FiO2 (or SpO2/FiO2) \<300;~6. Females of child-bearing potential and with an active sexual life must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:~   1. Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last IMP dose~  2. A non-hormonal intrauterine device \[IUD\] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last IMP dose~  3. A male sexual partner who agrees to use a male condom with spermicide~  4. A sterile sexual partner~Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, with child-bearing potential, pregnancy test result must be negative before first drug intake.~Exclusion Criteria:~1. Treatment with IMV or ECMO (NIAID-OS 7);~2. Hepatic dysfunction: ALT or AST \> 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score B or C);~3. Renal dysfunction: estimated glomerular filtration rate (eGFR, MDRD) \<50 mL/min/1.73 m2, or need for haemodialysis or hemofiltration;~4. Current use of \>2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anaemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC \< local LLN), solid organ or bone marrow transplant recipients)~5. Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period (see section 5.5.2);~6. Anticipated discharge from the hospital or transfer to another hospital within 72 hours of screening~7. History of:~   1. intolerance or hypersensitivity to ibuprofen to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib (hypersensitivity to sulphanilamide antibiotics alone, e.g. sulfamethoxazole does not qualify for exclusion)~  2. lactase deficiency, galactosemia or glucose-galactose malabsorption~  3. gastrointestinal bleeding or perforation due to previous NSAIDs therapy or recurrent peptic ulcer/haemorrhage~  4. allergy to reparixin or any component of the IMP formulation~8. Active bleeding or bleeding diathesis (excluding menses), prior intracranial haemorrhage~9. Participation in other interventional clinical trials~10. Clinical condition not compatible with oral administration of the study drug~11. Pregnancy:~    1. positive or missing pregnancy test before first drug intake or day 1;~   2. pregnant or lactating women;~   3. women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study~12. Current hospital stay \>72h~13. Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reparixin + standard of care (Type: EXPERIMENTAL): Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days.~The three daily doses will be administered maintaining an interval between doses of about 8 hours.
- Placebo + standard of care (Type: PLACEBO_COMPARATOR): Placebo tablets are identical in appearance to the active formulation. Placebo will be administered with the same treatment schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).